Solid Biosciences (SLDB)
NASDAQ:SLDB
Want to see SLDB full AI Analyst Report?
Top Page
Solid Biosciences
(NASDAQ:SLDB)
Select Model
Select Model
Rating:52Neutral
Price Target:
$8.50
▼(-1.51% Downside)
Action:Reiterated
Date:06/19/26
The score is held down primarily by weak financial performance (minimal revenue, widening losses, and heavy ongoing cash burn). Technicals are a meaningful offset with improving momentum and price strength versus major moving averages. Valuation remains pressured by unprofitability, while the authorized-share increase adds financing flexibility but introduces dilution risk.
Positive Factors
Contract manufacturing revenue stream
The majority-owned Solid Biologics unit produces recurring, fee-for-service revenue from viral vector development and GMP manufacturing. That service business diversifies cash generation away from binary clinical outcomes, provides steady customer demand, and supports operational continuity while therapeutics remain pre-commercial.
Negative Factors
High cash burn and negative free cash flow
Persistent, very large negative free cash flow creates structural funding pressure; operating cash generation does not cover expenses and the company must repeatedly access capital markets or partners to fund operations. This elevates dilution and execution risk absent sustained cash inflows.
Read all positive and negative factors
Positive Factors
Negative Factors
Contract manufacturing revenue stream
The majority-owned Solid Biologics unit produces recurring, fee-for-service revenue from viral vector development and GMP manufacturing. That service business diversifies cash generation away from binary clinical outcomes, provides steady customer demand, and supports operational continuity while therapeutics remain pre-commercial.
Read all positive factors
Solid Biosciences (SLDB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$820.09M
Dividend YieldN/A
Average Volume (3M)1.72M
Price to Earnings (P/E)―
Beta (1Y)1.85
Revenue GrowthN/A
EPS Growth34.94%
CountryUS
Employees100
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.95
Shares Outstanding98,449,610
10 Day Avg. Volume2,925,807
30 Day Avg. Volume1,724,204
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.74
Price to Sales (P/S)0.00
P/FCF Ratio-3.13
Enterprise Value/Market Cap0.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-374.46
Enterprise Value/Ebitda-1.54
Forecast
1Y Price Target
$16.75Price Target Upside94.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.91
Revenue Forecast (FY)N/A
Solid Biosciences Business Overview & Revenue Model
Company Description
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical...
How the Company Makes Money
Solid Biosciences has historically generated revenue primarily from its contract development/manufacturing and related services business (Solid Biologics), which provides process development, analytical development, and GMP manufacturing services ...
Solid Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
56
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 8.09M | 13.62M |
| Gross Profit | -781.00K | -1.64M | -2.46M | -2.58M | 8.09M | 13.62M |
| EBITDA | -190.10M | -172.69M | -121.90M | -93.43M | -96.87M | -69.22M |
| Net Income | -191.78M | -174.32M | -124.70M | -96.02M | -85.98M | -72.19M |
Balance Sheet | ||||||
| Total Assets | 422.89M | 232.54M | 188.66M | 164.94M | 260.25M | 232.38M |
| Cash, Cash Equivalents and Short-Term Investments | 381.32M | 187.85M | 148.92M | 123.64M | 213.72M | 207.78M |
| Total Debt | 20.67M | 21.16M | 24.18M | 26.27M | 28.55M | 2.06M |
| Total Liabilities | 48.76M | 52.53M | 51.42M | 38.46M | 48.59M | 24.17M |
| Stockholders Equity | 374.13M | 180.01M | 137.25M | 126.48M | 211.67M | 208.21M |
Cash Flow | ||||||
| Free Cash Flow | -172.86M | -157.44M | -100.67M | -95.69M | -100.99M | -79.05M |
| Operating Cash Flow | -171.67M | -156.29M | -100.01M | -94.18M | -97.98M | -77.76M |
| Investing Cash Flow | 13.77M | -58.45M | -16.09M | 9.69M | 59.16M | -91.09M |
| Financing Cash Flow | 243.75M | 194.45M | 122.44M | 3.12M | 74.83M | 134.99M |
Solid Biosciences Technical Analysis
Positive
8.63
Price Trends
7.35
Positive
7.07
Positive
6.28
Positive
Market Momentum
0.10
Negative
64.16
Neutral
78.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLDB, the sentiment is Positive. The current price of 8.63 is above the 20-day moving average (MA) of 7.00, above the 50-day MA of 7.35, and above the 200-day MA of 6.28, indicating a bullish trend. The MACD of 0.10 indicates Negative momentum. The RSI at 64.16 is Neutral, neither overbought nor oversold. The STOCH value of 78.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SLDB.
Solid Biosciences Risk Analysis
Solid Biosciences disclosed 90 risk factors in its most recent earnings report. Solid Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Solid Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $401.90M | -1.39 | -128.53% | ― | 928.46% | -21.39% | |
55 Neutral | $1.55B | -9.23 | -40.99% | ― | -73.07% | -2335.85% | |
52 Neutral | $820.09M | -4.77 | -74.45% | ― | ― | 34.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $187.35M | -1.33 | -117.86% | ― | -20.31% | -23.75% | |
42 Neutral | $138.64M | -1.23 | 65.27% | ― | 4.43% | 27.41% |
* Healthcare Sector Average
SLDB
Solid Biosciences
8.33
3.82
84.70%
AUTL
Autolus Therapeutics
1.51
-0.70
-31.67%
KRRO
Korro Bio
12.99
1.24
10.55%
ADCT
ADC Therapeutics
1.09
-1.59
-59.33%
GLUE
Monte Rosa Therapeutics
18.31
13.67
294.61%
Solid Biosciences Corporate Events
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Solid Biosciences Shareholders Approve Directors and Share Increase
Positive
Jun 10, 2026
At its June 10, 2026 annual meeting, Solid Biosciences stockholders elected Clare Kahn, Adam Stone and Lynne Sullivan as Class II directors to serve until the 2029 annual meeting, and ratified, on an advisory basis, the appointment of Ilan Ganot a...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Solid Biosciences Adjusts Board Classes in Governance Move
Neutral
Apr 10, 2026
Solid Biosciences Inc. announced changes to its Board of Directors structure, effective April 10, 2026, to achieve an equal balance of membership among its three director classes. Director Ilan Ganot resigned from his Class III seat, the number of...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.